AEON Biopharma, Inc. (AEON) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
AEON Biopharma, Inc. stock (AEON) is currently trading at $1.06. AEON Biopharma, Inc. PS ratio (Price-to-Sales) is 97.16. Analyst consensus price target for AEON is $7.20. WallStSmart rates AEON as Sell.
- AEON PE ratio analysis and historical PE chart
- AEON PS ratio (Price-to-Sales) history and trend
- AEON intrinsic value — DCF, Graham Number, EPV models
- AEON stock price prediction 2025 2026 2027 2028 2029 2030
- AEON fair value vs current price
- AEON insider transactions and insider buying
- Is AEON undervalued or overvalued?
- AEON Biopharma, Inc. financial analysis — revenue, earnings, cash flow
- AEON Piotroski F-Score and Altman Z-Score
- AEON analyst price target and Smart Rating
AEON Biopharma, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
AEON Biopharma, Inc. (AEON) · 3 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and price/sales. Significant fundamental concerns warrant caution or avoidance.
AEON Biopharma, Inc. (AEON) Key Strengths (0)
Supporting Valuation Data
AEON Biopharma, Inc. (AEON) Areas to Watch (3)
Very expensive at 97.2x annual revenue
Very low institutional interest at 12.57%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
AEON Biopharma, Inc. (AEON) Detailed Analysis Report
Overall Assessment
This company scores 6/100 in our Smart Analysis, earning a F grade. Out of 3 metrics analyzed, 0 register as strengths (avg 0/10) while 3 fall into concern territory (avg 2.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Price/Sales, Institutional Own., Market Cap. Some valuation metrics including Price/Sales (97.16) suggest expensive pricing.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Sales improves, as this is the primary drag on the overall score. Second, overall profitability trends. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Price/Sales and Institutional Own. are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
AEON Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
AEON's Price-to-Sales ratio of 97.16x trades 185% above its historical average of 34.15x (91th percentile), historically expensive. The current valuation is 0% below its historical high of 97.16x set in Mar 2026, and 16093% above its historical low of 0.6x in Jan 2025. Over the past 12 months, the PS ratio has expanded from ~2.7x, reflecting growing market expectations outpacing revenue growth.
Insider Transactions
Loading insider activity...
About AEON Biopharma, Inc.(AEON)
NYSE MKT
HEALTHCARE
BIOTECHNOLOGY
USA
AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. The company is headquartered in Newport Beach, California.